Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 8, 2025 (12 months ago)

Fasenra (benralizumab)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility:

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30

Affected NDC 0310-1730-30

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Fasenra
Benralizumab
NDC 00310-1730
30 mg/mL Injection, Solution
Subcutaneous
AstraZeneca Pharmaceuticals LP Rx
Recalling firm
Astrazeneca Pharmaceuticals
NDC code
0310-1730-30
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0028-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other sterility / contamination recalls from 2025

All sterility / contamination recalls
Class II · Moderate risk

Vista Gonio Eye Lubricant

Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

Ongoing Sterility / contamination Wizcure Pharmaa Private Limited NDC 77790-022-15 D-0349-2026